SCHEMBL3492239

SCHEMBL3492239

NNC(=O)c1ccc2occ(-c3ccccc3Cl)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.44
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
BCAT1 P54687 2/20 0.41
HTR1A P08908 1/20 0.41
HTR1D P28221 1/20 0.41
HTR2C P28335 1/20 0.41
CHRNA7 P36544 2/20 0.40
HTR3A P46098 1/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
KCNA3 P22001 1/20 0.39
MTNR1A P48039 2/20 0.39
MAOB P27338 1/20 0.38
NQO2 P16083 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3492780 0.82 NQO2 (0.49) ALDH1A1MAPTL3MBTL1LMNAKCNA3
SCHEMBL3492865 0.79 CNR1 (0.40) HDAC6HDAC3HDAC1HDAC2HDAC8
SCHEMBL3493539 0.76 ALDH1A1 (0.41) HDAC3HDAC1HDAC2HTR1AHTR1D
SCHEMBL3490841 0.76 AR (0.41) HDAC6HDAC1HDAC8HTR1AHTR1D
SCHEMBL3491008 0.74 OGG1 (0.47) HTR1AHTR1DHTR2CALDH1A1MAPT
SCHEMBL3490849 0.72 CA1 (0.55) HDAC6ALDH1A1MAPTKDM4ELMNA
SCHEMBL3491848 0.72 GSK3B (0.52) HTR1AHTR1DHTR2CALDH1A1MAPT
SCHEMBL28227887 0.70 KCNA3 (0.42) KCNA3MAOB
SCHEMBL3493569 0.70 FFAR1 (0.44) HDAC6HDAC1MAPTMAOB
SCHEMBL3491316 0.70 HDAC6 (0.47) HDAC6HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492378-B2 GSK-3β inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-23 US disclosed
US-20100069381-A1 GSK-3BETAINHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069381-A1 GSK-3BETAINHIBITOR GSK3B, GSK3A, GSKIP HDAC6 267/4885HDAC3 96/4885HDAC1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.